Why Patients Skip Medications—And How Systems Can Help: New Developments and Ongoing Strategies

Medication nonadherence remains a formidable obstacle in managing chronic diseases such as type 2 diabetes, despite significant advancements in therapies, policy reforms, and patient support initiatives. Recent developments underscore both the progress made and the complex, persistent challenges, emphasizing the urgent need for comprehensive, integrated approaches that combine clinical interventions, policy initiatives, safety transparency, and innovative communication strategies.

The Persistent Challenge of Medication Nonadherence

Research consistently shows that adherence rates for glucose-lowering medications in type 2 diabetes hover between 41% and 68%, varying by drug class and patient demographics. This gap between prescribed treatment and actual patient behavior results in suboptimal glycemic control, increasing the likelihood of severe complications—including cardiovascular disease, neuropathy, and retinopathy—and elevating healthcare costs. Studies estimate that 30–60% of patients encounter difficulties with adherence, driven by multiple intertwined factors:

• High out-of-pocket costs and financial barriers
• Side effects and adverse reactions
• Complex dosing regimens and medication schedules
• Limited understanding of disease progression and the importance of therapy
• Challenges in information sharing and support, especially among older adults managing medications at home

Understanding these barriers is essential for designing interventions that are both effective and sustainable.

Clinical and Systemic Responses: Enhancing Support and Education

Healthcare providers, particularly pharmacists, are pivotal in tackling nonadherence. They offer personalized counseling, medication therapy management, and ongoing monitoring to identify obstacles, manage side effects, and motivate patients. Evidence demonstrates that pharmacist-led interventions significantly improve adherence and clinical outcomes, especially among vulnerable groups such as seniors and underserved communities.

Patient education also remains a cornerstone. Empowering individuals with knowledge about their condition, medication purpose, and lifestyle modifications fosters greater engagement and ownership of health. However, recent qualitative research, including a study published in BMC Primary Care, highlights a significant challenge: ineffective information sharing for older adults managing medications at home. Many seniors face difficulties understanding instructions, accessing relevant information, or acting upon it—particularly when communication is fragmented or support systems are lacking.

Challenges in Home-Based Medication Support

Effective medication management at home involves navigating complex coordination. Key issues include:

• Limited access to timely and clear information
• Difficulty in understanding instructions without direct support
• Lack of seamless communication between healthcare providers and caregivers
• Insufficient health literacy and technological barriers

Addressing these issues calls for innovative solutions that facilitate smooth information sharing and empower older adults in their medication routines.

The Role of Technology and Caregiver Engagement

Emerging strategies emphasize the integration of digital tools—such as medication reminder apps, telepharmacy consultations, and electronic health records—to improve communication. Caregiver involvement is also crucial; training family members or community health workers can help bridge gaps in understanding and adherence, especially in home settings.

Policy Progress: Lowering Costs and Expanding Access

Recent policy initiatives have made notable strides in reducing financial hurdles:

• The Biden administration's law that reduced out-of-pocket costs for drugs under Medicare Part D has been associated with a significant decline in cost-related medication nonadherence among beneficiaries. These reforms make it more feasible for patients to stay on their medications without financial stress.

Building on these gains, bipartisan legislation introduced by Senators Susan Collins (R-ME) and J. Shaheen (D-NH) aims to further expand access and education:

Key provisions of the proposed bill include:

• Expanding access to newer, more effective diabetes medications without prohibitive costs
• Funding comprehensive diabetes education programs to enhance self-management skills
• Enhancing coverage for essential supplies such as insulin, glucose monitors, and related devices to address logistical and financial barriers

Senator Collins emphasized, “Our goal is to ensure that older Americans with diabetes receive the support they need to manage their condition effectively and maintain their quality of life.” If enacted, these measures could significantly improve adherence rates and health outcomes across populations.

Safety and Supply Concerns: Eroding Trust and Disrupting Access

While clinical and policy efforts advance, recent safety incidents threaten to undermine patient confidence and adherence. Notably, Eli Lilly issued an open letter warning about the detection of “impurities” in compounded tirzepatide combined with vitamin B12. Although details remain limited, this incident highlights critical issues:

• The importance of medication safety and quality control, especially for biologics and compounded drugs
• The risk that safety incidents could erode trust, leading patients to discontinue or hesitate before starting therapies
• The necessity for rigorous regulatory oversight and transparent communication** from manufacturers and authorities to reassure patients and providers

Adding to safety concerns is the broader U.S. drug supply crisis. Investigations and media reports reveal vulnerabilities within the supply chain, making it increasingly difficult for patients to access safe, reliable medications. A notable example is a recent YouTube documentary exploring these systemic issues, emphasizing that lack of transparency and quality assurance can severely impact adherence and trust.

Recent Evidence on Harmful Drug Combinations

Further compounding safety concerns are recent findings about medication combinations that pose significant risks. A detailed analysis titled "5 Medication Combinations Sending 177,000 Seniors to the ER Every Year" highlights how certain drug interactions—such as combinations involving anticholinergics, benzodiazepines, and other high-risk medications—are responsible for a staggering 177,000 emergency room visits annually among seniors. These incidents underscore the importance of careful prescribing, ongoing monitoring, and patient education to prevent adverse events that can lead to discontinuation or avoidance of necessary therapies.

Emerging Evidence on SGLT2 Inhibitors in Older and Frail Patients

A recent review in active medical journals sheds light on the evolving understanding of SGLT2 inhibitors among older and frail populations. While these drugs have demonstrated substantial benefits in reducing cardiovascular and renal complications, concerns about safety and tolerability in vulnerable groups have persisted.

The latest evidence indicates that with proper patient selection and vigilant monitoring, SGLT2 inhibitors can be safely prescribed to older adults, including those who are frail. Key insights include:

• The importance of evaluating individual risks such as volume depletion, urinary tract infections, and electrolyte imbalances
• The potential for these medications to improve quality of life and reduce hospitalizations when used judiciously
• The necessity for clinician education about tailored prescribing in this demographic

This nuanced perspective supports broader adoption of SGLT2 inhibitors, provided that healthcare providers incorporate careful assessment and ongoing management, which in turn can enhance adherence.

Moving Forward: Integrated Strategies for Better Adherence

Addressing medication nonadherence requires a holistic, multi-layered approach that combines clinical support, policy action, safety oversight, and technological innovation:

• Enhancing clinical supports through pharmacists, telehealth, caregiver training, and patient-centered education
• Continuing policy reforms to lower costs, expand access, and fund education programs
• Promoting transparency and safety oversight to rebuild trust, address supply chain vulnerabilities, and prevent adverse events
• Leveraging technology and community resources to improve home-based medication management, especially for older adults
• Ensuring regulatory vigilance to maintain medication quality and supply stability

Key next steps:

• Integrate digital tools like reminder apps and telepharmacy consultations to bridge communication gaps
• Advocate for legislative action—such as the bipartisan Collins–Shaheen bill—to sustain and expand support
• Increase transparency around safety incidents and supply issues to maintain patient confidence
• Train caregivers and patients in medication management best practices to reduce errors and improve adherence

Current Status and Implications

The bipartisan bill aimed at expanding access and education is currently under review in Congress, with stakeholders emphasizing its potential to significantly improve health outcomes for Medicare beneficiaries with diabetes. Meanwhile, safety concerns—such as Eli Lilly’s impurity alert—and systemic supply vulnerabilities highlight the ongoing need for vigilance, transparency, and proactive management.

In summary, combating medication nonadherence demands a comprehensive, multi-pronged strategy. By integrating clinical supports, supportive policies, safety transparency, and technological innovations, healthcare systems can better support patients—particularly older adults managing medications at home—to stay on prescribed therapies and achieve optimal health outcomes. Building trust, ensuring safety, and providing accessible, clear information will be critical in closing the adherence gap and improving quality of life for millions living with chronic conditions.